Nepal Krishus, Pant Narayan Dutt, Neupane Bibhusan, Belbase Ankit, Baidhya Rikesh, Shrestha Ram Krishna, Lekhak Binod, Bhatta Dwij Raj, Jha Bharat
Department of Microbiology, GoldenGate International College, Battisputali, Kathmandu, Nepal.
Department of Microbiology, Grande International Hospital, Dhapasi, Kathmandu, Nepal.
Ann Clin Microbiol Antimicrob. 2017 Sep 19;16(1):62. doi: 10.1186/s12941-017-0236-7.
Extended spectrum beta-lactamase (ESBL) and metallo beta-lactamase (MBL) production in Klebsiella pneumoniae and Escherichia coli are the commonest modes of drug resistance among these commonly isolated bacteria from clinical specimens. So the main purpose of our study was to determine the burden of ESBL and MBL production in E. coli and K. pneumoniae isolated from clinical samples. Further, the antimicrobial susceptibility patterns of E. coli and K. pneumoniae were also determined.
A cross-sectional study was conducted at Om Hospital and Research Centre, Kathmandu, Nepal by using the E. coli and K. pneumoniae isolated from different clinical samples (urine, pus, body fluids, sputum, blood) from May 2015 to December 2015. Antimicrobial susceptibility testing was performed by Kirby-Bauer disc diffusion technique. Extended spectrum beta-lactamase production was detected by combined disc method using ceftazidime and ceftazidime/clavulanic acid discs and cefotaxime and cefotaxime/clavulanic acid discs. Similarly, metallo beta-lactamase production was detected by combined disc assay using imipenem and imipenem/ethylenediaminetetracetate discs. Bacteria showing resistance to at least three different classes of antibiotics were considered multidrug resistant (MDR).
Of total 1568 different clinical samples processed, 268 (17.1%) samples were culture positive. Among which, E. coli and K. pneumoniae were isolated from 138 (51.5%) and 39 (14.6%) samples respectively. Of the total isolates 61 (34.5%) were ESBL producers and 7 (4%) isolates were found to be MBL producers. High rates of ESBL production (35.9%) was noted among the clinical isolates from outpatients, however no MBL producing strains were isolated from outpatients. Among 138 E. coli and 39 K. pneumoniae, 73 (52.9%) E. coli and 23 (59%) K. pneumoniae were multidrug resistant. The lowest rates of resistance was seen toward imipenem followed by piperacillin/tazobactam, amikacin and cefoperazone/sulbactam.
High rate of ESBL production was found in the E. coli and K. pneumoniae isolated from outpatients suggesting the dissemination of ESBL producing isolates in community. This is very serious issue and can't be neglected. Regular monitoring of rates of ESBL and MBL production along with multidrug resistance among clinical isolates is very necessary.
肺炎克雷伯菌和大肠埃希菌中产超广谱β-内酰胺酶(ESBL)和金属β-内酰胺酶(MBL)是从临床标本中常见分离出的这些细菌中最常见的耐药模式。因此,我们研究的主要目的是确定从临床样本中分离出的大肠埃希菌和肺炎克雷伯菌中产ESBL和MBL的情况。此外,还确定了大肠埃希菌和肺炎克雷伯菌的抗菌药敏模式。
在尼泊尔加德满都的奥姆医院和研究中心进行了一项横断面研究,使用2015年5月至2015年12月从不同临床样本(尿液、脓液、体液、痰液、血液)中分离出的大肠埃希菌和肺炎克雷伯菌。采用 Kirby-Bauer 纸片扩散法进行抗菌药敏试验。使用头孢他啶和头孢他啶/克拉维酸纸片以及头孢噻肟和头孢噻肟/克拉维酸纸片的联合纸片法检测超广谱β-内酰胺酶的产生。同样,使用亚胺培南和亚胺培南/乙二胺四乙酸纸片的联合纸片试验检测金属β-内酰胺酶的产生。对至少三类不同抗生素耐药的细菌被视为多重耐药(MDR)。
在总共处理的1568份不同临床样本中,268份(17.1%)样本培养呈阳性。其中,分别从138份(51.5%)和39份(14.6%)样本中分离出大肠埃希菌和肺炎克雷伯菌。在所有分离株中,61株(34.5%)是ESBL产生菌,7株(4%)分离株被发现是MBL产生菌。门诊患者临床分离株中ESBL产生率较高(35.9%),然而门诊患者中未分离出MBL产生菌株。在138株大肠埃希菌和39株肺炎克雷伯菌中,73株(52.9%)大肠埃希菌和23株(59%)肺炎克雷伯菌是多重耐药的。对亚胺培南的耐药率最低,其次是哌拉西林/他唑巴坦、阿米卡星和头孢哌酮/舒巴坦。
从门诊患者中分离出的大肠埃希菌和肺炎克雷伯菌中ESBL产生率较高,表明产ESBL分离株在社区中的传播。这是一个非常严重的问题,不能被忽视。定期监测临床分离株中ESBL和MBL的产生率以及多重耐药情况非常必要。